Globe Registry: Globe® Pulsed Field System Registry Study for Treating Patients With Symptomatic Atrial Fibrillation

Status

Not yet recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT07651852

Enrollment

500

Registered

2026-06-16

Start date

2026-07-01

Completion date

2029-10-01

Last updated

2026-06-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atrial Fibrillation

Brief summary

This post-market registry is designed to collect real world data on the use of the Globe PF System for the treatment of atrial fibrillation (AF).

Interventions

DEVICEGlobe Pulsed Field System

Ablation and atrial mapping with the Globe Pulsed Field System

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

Key Inclusion Criteria: * Patients with a planned ablation procedure using the commercially available Globe PF System Key

Exclusion criteria

* Patients whose life expectancy is 1 year or less * Contraindication to left atrial catheter ablation or PF ablation * Current enrollment in any investigational study of a medical device, biologic, or drug not pre-approved by Kardium

Design outcomes

Primary

Measure	Time frame	Description
Effectiveness endpoint	12 months	Rate of 12-month treatment success following ablation using the Globe PF System.
Safety endpoint	7 days	Rate of subjects with one or more major adverse events up to 7 days following the index ablation procedure.

Contacts

CONTACTClinical Affairs

Clinical.Affairs@kardium.com+1 (604) 248 8891

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jun 17, 2026